We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




10 Minute RT-PCR Point-of-Care System Detects Up To 32 Targets Per Sample

By LabMedica International staff writers
Posted on 21 Mar 2024

A 10-minute RT-PCR point-of-care (POC) system and respiratory panel are set to change the discussion on next-generation POC testing. More...

Autonomous Medical Devices Incorporated (AMDI, Santa Ana, CA, USA) is developing its Fast PCR System, a CLIA-waivable RT-PCR POC system that can detect up to 32 targets per sample in less than 10 minutes. The AMDI Fast PCR system is a compact, easy-to-use molecular point-of-care system that utilizes multiplexing capability specifically for CLIA-waived environments. It can run up to 32 targets at a time on a single sample in <10 minutes using a disposable disc without the need for a separate, offline sample preparation. At the core of the AMDI ultrafast system is the company’s Hyperbaric Heating (HBH) sample prep technology combined with its ultrafast PCR chemistry. The HBH technology eliminates the time constraints and costs associated with traditional sample preparation.

Combining HBH with AMDI’s ultrafast thermal cycling allows the test time to stay under 10 minutes regardless of the number of targets put on the test disc. The AMDI ultrafast system is designed to deliver highly sensitive, lab-quality results with the accessibility needed to address the testing needs of both the current and future pandemics. AMDI is also developing the first test panel for the Fast PCR system, targeting the detection of multiple respiratory viruses. The AMDI Respiratory Panel tests for the four most probable viruses that cause respiratory tract infections since the pandemic, including influenza A and B, respiratory syncytial virus, and SARS-CoV-2.

"Our market research indicates that our technology, when combined with cloud connectivity, can revolutionize patient care in the CLIA Waived setting," said David Okrongly, CEO of AMDI.

Related Links:
AMDI


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Acute lymphoblastic leukemia in children and young people requires careful relapse risk assessment as treatment expands beyond standard chemotherapy. (Image Credit: Shutterstock)

New Risk-Stratification Tool Predicts Relapse After Blinatumomab in Childhood ALL

Acute lymphoblastic leukemia in children and young people requires careful assessment of relapse risk, particularly as treatment approaches move beyond standard chemotherapy. Traditional relapse predictors... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Decentralized Laboratory Network Improves Detection of Viral Hemorrhagic Fevers in Guinea

Viral hemorrhagic fevers remain a major diagnostic challenge in West Africa because their early symptoms can resemble those of other febrile illnesses. The 2014–2016 Ebola epidemic underscored the need... Read more

Pathology

view channel
Image Credit: Adobe Stock

AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification

In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.